Skip to main content
Fig. 3 | European Journal of Medical Research

Fig. 3

From: The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials

Fig. 3Fig. 3

Meta-analysis of the neuroimaging and biomarkers outcomes under anti-amyloid-β monoclonal antibodies in patients with AD. Forest plot showed the comparisons of mean changes between drugs and placebo on neuroimaging and biomarkers outcomes:Changes in amyloid PET SUVr (a), Changes in CSF Aβ1-42 (b), Changes in CSF P-Tau (c), Changes in CSF T-Tau (d), Changes in plasma Aβ42/40 ratio (e), Changes in plasma p-tau181 (f)

Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us